Company intelligence / Profile preview

Aclarion, Inc.

Broomfield, Colorado, United Statesaclarion.com ↗

Ownership: Public · ACON
Employees: ~6
Development stage: Commercial

Overview

Aclarion’s NOCISCAN technology provides noninvasive identification of painful versus nonpainful spinal discs using MRS data and proprietary biomarkers. Clinical evidence shows an 85% improvement in patients treated based on these diagnostics. The pivotal CLARITY trial (up to 300 patients) began enrollment in late 2024 with interim data expected by Q1 2026 and full results by Q2 2026. Additional trials are underway to further validate efficacy

Therapeutic areas: Neurology
Modalities: Software-based diagnostics using magnetic resonance spectroscopy (MRS)proprietary biomarkers
Industry: Medical Imaging

Partnerships

Sheridan Community Hospital (Michigan)The London Clinic (UK)

Financials

Market cap: $1.3M
Total revenue: $25.2K
Enterprise value: $-15M

Beyond the preview

Go deeper on Aclarion, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aclarion, Inc..

Explore the full profile